Articles from VieCure

VieCure, a leading provider of intelligent software platforms for oncology care, has raised $43 million in funding to accelerate its mission to democratize access to precision medicine in community cancer care practices.

Today VieCure announced that the United States Patent & Trademark Office has issued VieCure’s patent, U.S. Patent No. 11,798,689 “Generating Customizable Personal Healthcare Treatment Plans”, covering the VieCure platform’s ability to use data and apply computerized algorithms to create healthcare treatment plans that are individualized for each patient’s unique circumstances.

VieCure today announced the go-live of OCP Miami as a part of VieCure’s strategic partnership with value-based care organization, Oncology Care Partners (“OCP”). The extension of this collaboration will assist OCP in its provision of world-class care to patients across its growing U.S. network, by supporting OCP’s providers in creating personalized treatment plans using VieCure’s Halo Intelligence Platform and helping OCP advance its commitment to overall health equity for its patients. This partnership is impactful as both companies are dedicated to revolutionizing the way that cancer patients are treated. OCP is committed to a new generation of cancer care, ensuring that patients are treated with “whole-person care,” giving them the opportunity to ensure the patient and family is supported and engaged throughout the entire care process. OCP has already opened its initial practice in Phoenix, Arizona, and is caring for Medicare Advantage patients in the surrounding area. It has also recently started offering care to patients in Miami, where it brings its value-based care model to patients. OCP is in the process of expanding to deliver world-class, community-based care throughout the country while striving for more efficient and individualized treatment options, and VieCure is proud to power all practices in its growing network. OCP is working to reduce unnecessary services which can in turn lower costs and reduce the burden placed on patients. Value-based care will ensure that patients receive the most comprehensive and efficient care, and in turn, improve the overall quality of life for patients and their families.

VieCure, a cancer care company with a market-leading artificial intelligence, informatics, and clinical decision support platform, announced today a new strategic collaboration with Clarified Precision Medicine which will make precision oncology more accessible for patients and community oncologists. In recent years there has been a large shift towards the use of patient-specific cancer treatment options that respond specifically to the molecular profile of the cancer (e.g., genomic data). These data points are complex, considerable, and difficult to access at the community oncology level based in part on the changing / updated tumor response data. This has highlighted a critical absence of medical guidance for both providers and payors and has motivated VieCure and Clarified Precision Medicine to work together to provide oncologists and their patients with clear, usable interpretations of any commercial comprehensive molecular profiling test along with a ranked list of treatment options which are reviewed by nationally recognized precision oncology experts. This partnership will also facilitate objective, third-party clinical review to assist a payor with prior authorization or an approval decision as part of the decision-making process for clinicians.

VieCure, a cancer care company with a market-leading artificial intelligence, informatics, and clinical decision support platform, announced today a strategic collaboration with Exact Sciences, a leading provider of cancer screening and diagnostic tests, to improve access to precision oncology diagnostics for patients and community oncologists within the United States.

VieCure today announced a new strategic partnership with value-based care organization, Oncology Care Partners (“OCP”), which will assist OCP in its provision of world-class care to patients across its growing U.S. network. This collaboration will support OCP’s providers in creating personalized treatment plans using VieCure’s Halo Intelligence Platform and help OCP to advance its commitment to overall health equity for the patients that they serve. This partnership will be impactful as both companies are dedicated to revolutionizing the way that cancer patients are treated. OCP is committed to a new generation of cancer care, ensuring that patients are treated with “whole-person care,” giving them the opportunity to ensure the patient and family will be supported and engaged throughout the entire care process. Currently, OCP has opened its initial practice in Phoenix, Arizona, and is caring for Medicare Advantage patients in the surrounding area. It has also recently acquired an existing practice in Miami, where it will bring its value-based care model to patients in South Florida. OCP is in the process of expanding to deliver world-class, community-based care throughout the country while striving for more efficient and individualized treatment options, and VieCure is proud to power all practices in its growing network. OCP is working to reduce unnecessary services which can in turn lower costs and lower the burden placed on patients. Value-based care will ensure that patients receive the most comprehensive and efficient care, and in turn, improve the overall quality of life for patients and their families.

The Postgraduate Institute for Medicine (PIM), which accredits more than 2,500 educational activities for healthcare professionals each year, and VieCure, a cancer care company with a powerful clinical decision support platform, are pleased to announce a new partnership designed to offer continuing medical education (CME) to the multidisciplinary cancer care teams utilizing the VieCure platform.

VieCure, a cancer care company with a market-leading artificial intelligence, informatics, and clinical decision support platform, announced today the opening of the Dr. Don Iverson Oncology Innovation Center. The Iverson Innovation Center is designed to simulate, for oncologists and cancer care thought leaders, the patient treatment experience in the new and emerging era of precision oncology. In recent years there has been a large shift towards the use of cancer treatments that respond specifically to the molecular profile of the cancer (e.g., genomic data). These data are complex, considerable, and difficult to access at the community oncology level. Next-generation sequencing testing (NGS) to identify the genomic drivers of a patient’s cancer is now foundational for precision oncology, with rapidly expanding diagnostic, prognostic, and therapeutic implications. Although few question the importance of NGS in modern oncology care, the process of gathering primary molecular data, integrating it into the patient's electronic health record, and optimally using it to assist with patient treatment decisions and as part of a clinical workflow remains far from seamless. Numerous challenges persist around data standards and interoperability, and clinicians frequently face difficulties in managing the growing amount of genomic knowledge required to care for patients and keep up to date.

VieCure, a cancer care company with a market leading artificial intelligence, informatics, and clinical decision support platform, announced today a new strategic collaboration with Clarified Precision Medicine which will make precision oncology more accessible for patients and community oncologists. In recent years there has been a large shift towards the use of cancer treatments which respond specifically to the molecular profile of the cancer (e.g., genomic data). These data are complex, considerable, and difficult to access at the community oncology level. This has highlighted a critical absence of medical guidance for both providers and payors and has motivated VieCure and Clarified Precision Medicine to work together to provide oncologists and their patients with clear, usable interpretations of any commercial comprehensive molecular profiling test along with a ranked list of treatment options which are reviewed by nationally recognized precision oncology experts. This partnership will also facilitate objective, third-party clinical review to assist a payor with prior authorization or an approval decision.

VieCure, a cancer care company, announced today at ASCO 2022, the release of its next generation oncology clinical decision support platform including the introduction of Halo Intelligence for oncologists. The reality of cancer medicine today is the ever-increasing complexity of diagnostics, treatment, and follow up care. “In the 1980s, medical data and evidence was doubling every 7 years but by 2020, it will double every 73 days,” says Dr. Fred Ashbury, PhD and Chief Scientific Officer for VieCure. “The FDA yearly cancer drug approvals increased 200% from 2010 to 2020.”

VieCure, a cancer care company with a market leading artificial intelligence, informatics, and clinical decision support platform, announced today the appointment of two new members to the Board of Directors: biopharmaceutical strategic advisor Michael Mentesana and Brad Prechtl, President and Chief Development Officer for the American Oncology Network (AON).

American Oncology Network, LLC (AON) , a high-growth medical oncology provider with a focus on supporting the long-term viability of oncology treatment in community-based settings, announced today a strategic collaboration with VieCure, a national leader in the deployment of Artificial Intelligence (AI), codified clinical content and point-of-care clinical decision support in oncology. The collaboration is designed to facilitate the delivery of precision oncology and personalized care and treatment for patients across the ever-expanding AON network.